Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1999 May;21(3):192-7.
doi: 10.1002/(sici)1097-0347(199905)21:3<192::aid-hed2>3.0.co;2-d.

Evaluation of glycoprotein constituents in head and neck cancer patients undergoing radiotherapy

R M Rawal  1 , P S Patel, B P Patel, G N Raval, M M Patel, J M Bhatavdekar, S A Dixit, D D Patel
Affiliations

Evaluation of glycoprotein constituents in head and neck cancer patients undergoing radiotherapy

R M Rawal et al. Head Neck. 1999 May.

Abstract

Background: Alterations in serum levels of several glycoprotein constituents are reported to be useful for treatment monitoring of cancer patients. The purpose of this study was to determine efficacy of sialic acid and seromucoid fraction as treatment monitors for head and neck (H&N) cancer patients undergoing radiotherapy (RT).

Methods: Serum levels of total sialic acid (TSA), lipid-bound sialic acid (LSA), and seromucoid fraction (measured as Mucoid protein [MP] and hexose) were studied in age matched controls and in patients with H&N cancer at diagnosis and during/after completion of RT. The markers were estimated by spectrophotometric methods.

Results: Serum levels of sialic acid forms and seromucoid fraction were significantly elevated (p<.001) in untreated H&N cancer patients (n = 32) as compared with controls (n = 50). The marker levels were significantly declined (p<.001) in H&N cancer patients who responded to RT as compared with their levels at diagnosis, whereas the levels were persistently elevated in nonresponders.

Conclusion: Evaluation of sialic acid forms and seromucoid fraction could be used for monitoring the treatment of H&N cancer patients undergoing RT.

PubMed Disclaimer

Publication types

LinkOut - more resources